文献速递乳腺癌

胰岛素样生长因子-1、胰岛素样生长因子结合蛋白-3与乳腺癌风险:约43万女性的观察性与孟德尔随机化分析

Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, and breast cancer risk: observational and Mendelian randomization analyses with ∼430 000 women.
PubMed 文献 · Ann Oncol · 2020-03-10

该研究在UK Biobank的206 263名女性中观察循环IGF-1与乳腺癌发病关联,并对回归稀释偏倚进行校正,同时利用122 977例病例和105 974例对照的基因组数据进行两样本孟德尔随机化分析。结果显示,校正后IGF-1每升高5 nmol/l与乳腺癌风险增加相关(HR=1.11,95%CI 1.07-1.16),遗传预测的IGF-1每升高5 nmol/l亦与风险增加相关(OR=1.05,95%CI 1.01-1.10;P=0.02),而遗传预测的IGFBP-3与乳腺癌风险无关。结论支持循环IGF-1与乳腺癌之间可能存在因果关联。

要点

  • 观察性分析校正回归稀释后,IGF-1每升高5 nmol/l与乳腺癌风险增加11%相关。
  • 孟德尔随机化显示遗传预测IGF-1每升高5 nmol/l与乳腺癌风险增加5%相关,支持因果关联。
  • 遗传预测IGFBP-3每升高1个标准差与乳腺癌风险无关(OR=1.00,95%CI 0.97-1.04;P=0.98)。

核心结论

  • 结果支持循环IGF-1浓度与乳腺癌之间可能存在因果关联,提示靶向IGF通路可能有助于预防乳腺肿瘤发生。

研究设计与样本

  • 在UK Biobank的206 263名女性中开展观察性分析,采用Cox比例风险模型估计多变量HR及95%CI,并利用6711名女性的重复IGF-1测量校正回归稀释。
  • 采用两样本孟德尔随机化分析,基于122 977例乳腺癌病例和105 974例对照的全基因组数据,评估遗传预测的IGF-1和IGFBP-3水平与乳腺癌风险的关联。

主要发现

  • UK Biobank中位随访7.1年,发生4360例新发乳腺癌。
  • 校正回归稀释的多变量模型中,IGF-1每升高5 nmol/l与乳腺癌风险增加相关(HR=1.11,95%CI 1.07-1.16)。
  • 按随访时间、绝经状态、体重指数及其他风险因素分层,均发现类似的阳性关联。
  • 孟德尔随机化分析中,遗传预测的IGF-1每升高5 nmol/l与乳腺癌风险增加相关(OR=1.05,95%CI 1.01-1.10;P=0.02),雌激素受体阳性肿瘤效应估计相似,雌激素受体阴性肿瘤未发现效应。
  • 遗传预测的IGFBP-3每升高1个标准差与乳腺癌风险无关(OR=1.00,95%CI 0.97-1.04;P=0.98)。

临床怎么用

  • 循环IGF-1水平可能作为乳腺癌风险相关的生物标志物,但尚需进一步研究验证其临床效用。
  • 靶向IGF通路的干预措施可能成为乳腺癌预防的潜在策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Epidemiological evidence supports a positive association between circulating insulin-like growth factor-1 (IGF-1) concentrations and breast cancer risk, but both the magnitude and causality of this relationship are uncertain. We conducted observational analyses with adjustment for regression dilution bias, and Mendelian randomization (MR) analyses allowed for causal inference. PATIENTS AND METHODS: We investigated the associations between circulating IGF-1 concentrations and incident breast cancer risk in 206 263 women in the UK Biobank. Multivariable hazard ratios (HRs) and 95% confidence intervals (CI) were estimated using Cox proportional hazards models. HRs were corrected for regression dilution using repeat IGF-1 measures available in a subsample of 6711 women. For the MR analyses, genetic variants associated with circulating IGF-1 and IGF-binding protein-3 (IGFBP-3) levels were identified and their association with breast cancer was examined with two-sample MR methods using genome-wide data from 122 977 cases and 105 974 controls. RESULTS: In the UK Biobank, after a median follow-up of 7.1 years, 4360 incident breast cancer cases occurred. In the multivariable-adjusted models corrected for regression dilution, higher IGF-1 concentrations were associated with a greater risk of breast cancer (HR per 5 nmol/l increment of IGF-1 = 1.11, 95% CI = 1.07-1.16). Similar positive associations were found by follow-up time, menopausal status, body mass index, and other risk factors. In the MR analyses, a 5 nmol/l increment in genetically-predicted IGF-1 concentration was associated with a greater breast cancer risk (odds ratio = 1.05, 95% CI = 1.01-1.10; P = 0.02), with a similar effect estimate for estrogen-positive (ER+) tumours, but no effect found for estrogen-negative (ER-) tumours. Genetically-predicted IGFBP-3 concentrations were not associated with breast cancer risk (odds ratio per 1-standard deviation increment = 1.00, 95% CI = 0.97-1.04; P = 0.98). CONCLUSION: Our results support a probable causal relationship between circulating IGF-1 concentrations and breast cancer, suggesting that interventions targeting the IGF pathway may be beneficial in preventing breast tumorigenesis.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Murphy N, Knuppel A, Papadimitriou N, et al. Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, and breast cancer risk: observational and Mendelian randomization analyses with ∼430 000 women. Ann Oncol. 2020. PMID: 32169310. doi:10.1016/j.annonc.2020.01.066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。